Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia

Prior treatment

• Major organ surgery within 6 weeks prior to enrollment.

Other illness

• Known hypersensitivity or contraindication to any study drug.
• Active infection.
• Psychiatric illness or other condition that prevents informed consent or compliance with study procedures.
• Any condition deemed unsuitable for the study by the investigator (e.g., poor compliance, substance abuse).

Lab values

• Abnormal liver function: total bilirubin \> 2× ULN, ALT/AST \> 2.5 × ULN; abnormal renal function: serum creatinine \> 1.5 × ULN.

Other

• Pregnancy or lactation.
• Long-term smoking or alcohol abuse that may interfere with study outcome evaluation.

• Voluntary participation with written informed consent signed by the participant or a legal guardian; willingness to comply with all study procedures.
• Age 14 to 60 years at screening, no gender restriction.
• Diagnosis of acute monocytic leukemia according to the 2016 WHO classification, excluding acute promyelocytic leukemia.
• No history of severe allergic reactions.
• Liver function: ALT and AST ≤ 2.5 × upper limit of normal (ULN); total bilirubin ≤ 2 × ULN.
• Renal function: serum creatinine ≤ 1.5 × ULN
• No uncontrolled infection or severe psychiatric disorder.
• ECOG performance status 0-3; life expectancy ≥ 4 months.